DISCUSSION Our case showed significant improvement of AA during dupilumab treatment
for AD. To date, Darrigade et al. reported a similar case (1), and Penzi et al.(2) reported a …

Discussion We report a temporal relationship between dupilumab and the subsequent
development of AA. Of course, temporal cannot be interpreted as causal; however, we …

We present a case report of a 42-year-old woman with severe atopic dermatitis (AD) and
history of alopecia areata (AA), which had been in remission for more than 5 years. She was …

Dupilumab, a biologic drug approved for the treatment of moderate‐to‐severe atopic
dermatitis, has been associated with resolution or improvement in pre‐existing alopecia …

Objective: Unusual or unexpected effect of treatment Background: Dupilumab is a relatively
new immune-modulating drug that has transformed the way clinicians treat common …

Alopecia areata in 2 patients treated with dupilumab: New onset and worsening - ScienceDirect
Skip to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …

Discussion AA is strongly associated with atopic diatheses, 4 and polymorphisms in
interleukin 4 (IL-4) and IL-13 have been described in patients with AA. 5, 6 The …

DEAR EDITOR, Alopecia areata (AA) is one of the most common autoimmune diseases;
however, the pathogenesis of the condition has yet to be fully elucidated. A recent study …

Dupilumab is the first targeted biologic approved for the treatment of moderate-to-severe
atopic dermatitis (AD). 1 Despite its safe efficacy profile, recent studies have reported both …

Alopecia areata (AA) is a chronic inflammatory disease mainly involving Th1
immunoreaction, but Th2 is also involved. A 9-year-old girl presented to our clinic with …